Evidence map›Paper›PMID 40738981›Full record

ArticleGastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association2025

Neoantigen mRNA vaccines induce progenitor-exhausted T cells that support anti-PD-1 therapy in gastric cancer with peritoneal metastasis.

Koji Nagaoka, Hideyuki Nakanishi, Hiroki Tanaka, Jessica Anindita, Takeshi Kawamura, Toshiya Tanaka, Takefumi Yamashita, Akihiro Kuroda, Sachiyo Nomura, Hidetaka Akita and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Koji Nagaoka *Department of Immunology, Kindai University, Faculty of Medicine, 377-2 Ohnohigashi, Osakasayama, Osaka, 589-0014, Japan.
Hideyuki Nakanishi *Department of Biofunction Research, Laboratory for Biomaterials and Bioengineering, Institute of Integrated Research, Institute of Science Tokyo, 2-3-10 Kanda-Surugadai, Chiyoda-Ku, Tokyo, 101-0062, Japan.
Hiroki Tanaka *Laboratory of DDS Design and Drug Disposition, Graduate School of Pharmaceutical Sciences, Tohoku University, 6-3 Aoba, Aramaki, Aoba-Ku, Sendai, 980-8578, Japan.
Jessica AninditaLaboratory of DDS Design and Drug Disposition, Graduate School of Pharmaceutical Sciences, Tohoku University, 6-3 Aoba, Aramaki, Aoba-Ku, Sendai, 980-8578, Japan.
Takeshi KawamuraIsotope Science Center, The University of Tokyo, 2-11-16 Yayoi, Bunkyo-Ku, Tokyo, 113-0032, Japan.
Toshiya TanakaLaboratories for Systems Biology and Medicine, Research Center for Advanced Science and Technology, The University of Tokyo, 4-6-1 Komaba, Meguro-Ku, Tokyo, 153-8904, Japan.
Takefumi YamashitaLaboratories for Systems Biology and Medicine, Research Center for Advanced Science and Technology, The University of Tokyo, 4-6-1 Komaba, Meguro-Ku, Tokyo, 153-8904, Japan.
Akihiro KurodaDepartment of Gastrointestinal Surgery, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-Ku, Tokyo, 113-8655, Japan.
Sachiyo NomuraIsotope Science Center, The University of Tokyo, 2-11-16 Yayoi, Bunkyo-Ku, Tokyo, 113-0032, Japan.
Hidetaka AkitaLaboratory of DDS Design and Drug Disposition, Graduate School of Pharmaceutical Sciences, Tohoku University, 6-3 Aoba, Aramaki, Aoba-Ku, Sendai, 980-8578, Japan.
Keiji ItakaDepartment of Biofunction Research, Laboratory for Biomaterials and Bioengineering, Institute of Integrated Research, Institute of Science Tokyo, 2-3-10 Kanda-Surugadai, Chiyoda-Ku, Tokyo, 101-0062, Japan.
Tatsuhiko KodamaLaboratories for Systems Biology and Medicine, Research Center for Advanced Science and Technology, The University of Tokyo, 4-6-1 Komaba, Meguro-Ku, Tokyo, 153-8904, Japan.
Kazuhiro KakimiDepartment of Immunology, Kindai University, Faculty of Medicine, 377-2 Ohnohigashi, Osakasayama, Osaka, 589-0014, Japan. kakimi@med.kindai.ac.jp.ORCID 0000-0003-2631-3040

Funding

Japan Agency for Medical Research and Development JP223fa627002Japan Society for the Promotion of Science 21K18320Japan Society for the Promotion of Science 23H00319Japan Society for the Promotion of Science 23K08188Japan Society for the Promotion of Science 23K27453Japan Society for the Promotion of Science 24K02393
6 · The paper itself

Abstract

backgroundGastric cancer with peritoneal metastasis is associated with a poor prognosis. Current treatments, including the first-line therapy of combination chemotherapy with nivolumab for advanced recurrent gastric cancer, have shown limited efficacy against peritoneal dissemination. In this study, we evaluated neoantigen (neoAg)-mRNA lipid nanoparticle (LNP) as a potential agent in combination with anti-PD-1 therapy, focusing on its effects on neoAg-specific CD8

methodsThe mRNA, comprising a tandem minigene encoding three neoAgs identified from the murine gastric cancer YTN16 cell line, was synthesized by in vitro transcription and encapsulated within LNPs. NeoAg-specific CD8

resultsThe neoAg-mRNA-LNP vaccine induced significantly higher frequencies of neoAg-specific CD8

conclusionsNeoAg-mRNA-LNP vaccines elicit potent neoAg-specific CD8

Indexed as

Antigens, NeoplasmCancer VaccinesCD8-Positive T-LymphocytesImmune Checkpoint InhibitorsmRNA VaccinesPeritoneal NeoplasmsStomach NeoplasmsAnimalsCell Line, TumorFemaleHumansMiceNanoparticlesProgrammed Cell Death 1 ReceptorAntigens, NeoplasmCancer VaccinesImmune Checkpoint InhibitorsmRNA VaccinesProgrammed Cell Death 1 ReceptorGastric cancerImmune checkpoint inhibitormRNA vaccineNeoantigenPeritoneal metastasis

Identifiers

PMID40738981
PMCPMC12378472

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.